Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Dec;7(6):860-3.
doi: 10.3748/wjg.v7.i6.860.

Fas counterattack in cholangiocarcinoma: a mechanism for immune evasion in human hilar cholangiocarcinomas

Z Y Li  1 , S Q Zou
Affiliations

Fas counterattack in cholangiocarcinoma: a mechanism for immune evasion in human hilar cholangiocarcinomas

Z Y Li et al. World J Gastroenterol. 2001 Dec.

Abstract

Aim: To investigate FasL expression in hilar cholangiocarcinoma tissues and cultured cholangiocarcinoma cells, and to assess its ability to induce apoptosis.

Methods: We studied the expression of FasL by human hilar cholangiocaroinomas tissues by immunohistochemistry, and the QBC939 cholangiocarcinoma cell line by RT-PCR, immunohistochemistry, and Western Blot. TUNEL and flow cytometry were used to detect apoptotic cells.

Results: Prevalent expression of FasL was detected in 39 resected hilar cholangiocarcinoma tissues. TUNEL staining disclosed a high level of cell death among lymphocytes infiltrating FasL positive areas of tumor. FasL mRNA and protein expressions in cholangiocarcinoma cells could induce Jurkat cells.

Conclusion: Hilar cholangiocarcinomas may elude immunological surveillance by inducing, via Fas/FasL system, the apoptosis of activated lymphocytes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
FasL positive in human hilar cholangiocarcinom as (brown). SABC × 200
Figure 2
Figure 2
Expression of FasL in cholangiocarcinoma cell line. QBC939 × 200
Figure 3
Figure 3
Expression of FasL mRNA in human cholangiocarcinoma cells QBC939. M: DL 2000 Marker; 1: FasL; 2: FasL+β-actin
Figure 4
Figure 4
CD45 positive cells (brown) of lymphoid morphology adjacent to carcinoma. × 200
Figure 5
Figure 5
Positive apoptotic TUNEL stainig in situ (brown) with apoptotic morphology.
Figure 6
Figure 6
Western blotting of FasL protein with mAb from QBC939 cell cultures clone 33 from QBC939 cell cultures
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189–1192. - PubMed
    1. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature. 1995;377:630–632. - PubMed
    1. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449–1456. - PubMed
    1. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med. 1995;181:71–77. - PMC - PubMed
    1. Gu XH, Li QF, Wang YM. Expression of hepatocyte apoptosis and Fas/Fas L, in liver tissues of patients with hepatitis D. Shijie Huaren Xiaohua Zazhi. 2000;8:35–38.